Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review (vol 11, pg 1, 2019)

被引：0
|
作者：
Chiorean, Elena Gabriela
Cheung, Winson Y.
Giordano, Guido
Kim, George
Al-Batran, Salah-Eddin
机构：
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2019年 / 11卷
关键词：
D O I：
10.1177/1758835919871363
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
    Prejac, Juraj
    Hamzic, Dora Tomek
    Librenjak, Niksa
    Gorsic, Irma
    Kekez, Domina
    Plestina, Stjepko
    MEDICINE, 2022, 101 (39) : E30566
  • [32] Retrospective analysis of institutional outcomes with FOLFIRINOX versus nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer
    Singh, Amisha
    Shroff, Rachna T.
    McBride, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [33] Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in locally advanced/borderline resectable pancreatic cancer patients.
    Ingram, Myles
    Lauren, Brianna N.
    Pumpalova, Yoanna S.
    Manji, Gulam Abbas
    Bates, Susan Elaine
    Hur, Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] FOLFIRINOX for advanced pancreatic cancer patients after nab-paclitaxel plus gemcitabine failure: retrospective analysis
    Matsumoto, Toshihiko
    Kimura, Shogo
    Himei, Hitomi
    Okazaki, Ukyo
    Kurioka, Yusuke
    Tsuduki, Takao
    Takagi, Shijiro
    Takatani, Masahiro
    Hiramatsu, Ysushi
    Morishita, Hirofumi
    ANNALS OF ONCOLOGY, 2019, 30
  • [35] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
  • [36] Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel
    Ide, Yasushi
    Otsuka, Taiga
    Shimokawa, Mototsugu
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Fukahori, Masaru
    Makiyama, Akitaka
    Shinohara, Yudai
    Ueno, Shohei
    Taguchi, Hiroki
    Honda, Takuya
    Shibuki, Taro
    Nio, Kenta
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    ANTICANCER RESEARCH, 2023, 43 (04) : 1817 - 1826
  • [37] Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer
    Chiorean, E. Gabriela
    Whiting, Scott
    Binder, Gary
    Dranitsaris, George
    Manax, Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [38] Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer A Multicenter Observational Study (NAPOLEON Study)
    Arima, Shiho
    Kawahira, Machiko
    Shimokawa, Mototsugu
    Ido, Akio
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Fukahori, Masaru
    Makiyama, Akitaka
    Taguchi, Hiroki
    Honda, Takuya
    Shibuki, Taro
    Mitsugi, Kenji
    Nio, Kenta
    Ide, Yasushi
    Ureshino, Norio
    Mizuta, Toshihiko
    Shirakawa, Tsuyoshi
    Otsuka, Taiga
    PANCREAS, 2021, 50 (07) : 957 - 964
  • [39] The retrospective analysis of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer
    Ueno, M.
    Kobayashi, S.
    Ohkawa, S.
    Tezuka, S.
    Moriya, S.
    Morimoto, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 67 - 67
  • [40] Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
    Hakon Blomstrand
    Ursula Scheibling
    Charlotte Bratthäll
    Henrik Green
    Nils O. Elander
    BMC Cancer, 19
12345